Abstract:Sleep apnea involves almost one billion individuals throughout the world, including 40 million Americans. Of major medical concern is the fact that the prevalence of sleep apnea is significantly increasing due to the epidemic of obesity, physical inactivity, and diabetes mellitus which are important risk factors for the development and persistence of sleep apnea in individuals. Sleep apnea is characterized by multiple episodes of apnea or hypopnea during sleep, which cause nocturnal arousals, gasping for breath during the night, daytime sleepiness, irritability, forgetfulness, fatigue and recurrent headaches. Obstructive sleep apnea occurs when upper airway obstruction occurs in an individual during sleep with absent or markedly reduced airflow in the presence of continued activity of inspiratory thoracic and diaphragmatic muscles. Central sleep apnea is defined as the absence or the significant reduction of naso-oral airflow due to the withdrawal during sleep of ponto-medullary respiratory center stimulation of the nerves of the inspiratory thoracic and diaphragmatic muscles and absence of contraction of these muscles during apnea. Complex sleep apnea occurs when an individual exhibits characteristics of both obstructive and central sleep apnea. The severity of sleep apnea is measured by polysomnography and the apnea hypopnea index (AHI), which is the average number of apneas and hypopneas per hour of sleep measured by polysomnography. Sleep apnea is mild if the AHI is 5-14/hour with no or mild symptoms, moderate if the AHI is 15 to 30/hour with occasional daytime sleepiness, and severe if the AHI is >30/hour with frequent daytime sleepiness that interferes with the normal activities of daily life. Chronic sleep apneas and hypopneas followed by compensatory hyperpneas are associated with significant adverse cardiovascular consequences including: 1) recurrent hypoxemia and hypercarbia; 2) Increased sympathetic nerve activity and decreased parasympathetic nerve activity; 3) oxidative stress and vascular endothelial dysfunction; and 4) cardiac remodeling and cardiovascular disease. Moderate or severe sleep apnea significantly increases the risk of coronary artery disease, congestive heart failure, cerebral vascular events (strokes), and cardiac dysrhythmias, and also increase the morbidity and mortality of these diseases. Nevertheless, sleep apnea is currently underdiagnosed and untreated in many individuals due to the challenges in the prediction and detection of sleep apnea and a lack of well-defined optimal treatment guidelines. Chronic continuous positive airway pressure for ≥4 hours/night for >70% of nights is beneficial in the treatment of patients with sleep apnea. CPAP Improves sleep quality, reduces the AHI, augments cardiac output and increases oxygen delivery to brain and heart, reduces resistant hypertension, decreases cardiac dysrhythmias, and reduces daytime sleepiness. The present article discusses the diagnosis of obstructive sleep apnea, central sleep apnea, and complex apnea. Thereafter the important pathophysiologic mechanisms in sleep apnea and the relationship of these pathophysiologic mechanics to atherosclerotic vascular disease are reviewed. Guidelines are then provided for the treatment of mild, moderate and severe sleep apnea In order to reduce the cardiovascular morbidity and mortality caused by sleep apnea and facilitate the diagnosis and the long-term, effective treatment of sleep apnea in patients, the close cooperation is necessary of cardiovascular specialists, pulmonary specialists, and respiratory therapy/ rehabilitation specialists.

Sleep apnea-plus: prevalence, risk factors, and association with cardiovascular diseases using United States population-level data

Cardiovascular and Psychiatric Morbidity in Obstructive Sleep Apnea (OSA) with Insomnia (Sleep Apnea Plus) versus Obstructive Sleep Apnea without Insomnia: A Case-Control Study from a Nationally Representative US Sample

Obstructive Sleep Apnea and Its Cardiac Implications in the United States: An Age-Stratified Analysis Between Young and Older Adults

0493 Characteristics of Middle-Aged and Older Adults with Comorbid Insomnia and Sleep Apnea vs. Sleep Apnea Alone

Obstructive sleep apnea: implications for cardiac and vascular disease

Abstract MP68: Risk of Sleep Apnea and Subclinical Cardiovascular Disease in Young-to-Middle Aged Adults: The Bogalusa Heart Study

Association Between Obstructive Sleep Apnea and Cardiovascular Diseases.

The Link Between Obstructive Sleep Apnea and Cardiovascular Disease

The association between high risk of sleep apnea, comorbidities, and risk of COVID-19: a population-based international harmonized study

Obstructive sleep apnea comorbid with insomnia symptoms and objective short sleep duration is associated with clinical and preclinical cardiometabolic risk factors: Clinical implications

0866 Prevalence of Obesity in Obstructive Sleep Apnea Within a Large Community-based Cohort of Middle-aged/Older Adults

A cross-sectional study of the correlation of the ratio of non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol (NHHR) with obstructive sleep apnea (OSA) in adult populations: NHANES (2005–2008 and 2015–2020)

Association Between Obstructive Sleep Apnea and Cardiovascular Risk Factors: Variation by Age, Sex, and Race. the Multi-Ethnic Study of Atherosclerosis.

Comorbid insomnia and sleep apnoea is associated with all-cause mortality

Cardiovascular Risk in Young Patients Diagnosed With Obstructive Sleep Apnea

SLEEP APNEA IS A COMMON AND DANGEROUS CARDIOVASCULAR RISK FACTOR

Co-morbid insomnia and sleep apnoea is associated with increased hypertension risk in a middle-aged population

Comorbidities in coexisting chronic obstructive pulmonary disease and obstructive sleep apnea - overlap syndrome

Obstructive sleep apnoea and comorbidity - an overview of the association and impact of continuous positive airway pressure therapy

Association of sleep characteristics with cardiovascular disease risk in adults over 40 years of age: a cross-sectional survey

0722 Clinical, Demographic, Functional, and Symptom Correlates of COMISA in Stable Heart Failure